Thromb Haemost 1989; 62(03): 934-939
DOI: 10.1055/s-0038-1651031
Original Article
Schattauer GmbH Stuttgart

Epitope Mapping of the Anti-Urokinase Monoclonal Antibody 5B4 by Isolated Domains of Urokinase

Angelo Corti
Merrell Dow Research Institute, Lepetit Research Center, Gerenzano (Varese), Italy
,
Edoardo Sarubbi
Merrell Dow Research Institute, Lepetit Research Center, Gerenzano (Varese), Italy
,
Adolfo Soffientini
Merrell Dow Research Institute, Lepetit Research Center, Gerenzano (Varese), Italy
,
M Luisa Nolli
Merrell Dow Research Institute, Lepetit Research Center, Gerenzano (Varese), Italy
,
Arturo Zanni
Merrell Dow Research Institute, Lepetit Research Center, Gerenzano (Varese), Italy
,
Marina Galimberti
Merrell Dow Research Institute, Lepetit Research Center, Gerenzano (Varese), Italy
,
Franco Parenti
Merrell Dow Research Institute, Lepetit Research Center, Gerenzano (Varese), Italy
,
Giovanni Cassani
Merrell Dow Research Institute, Lepetit Research Center, Gerenzano (Varese), Italy
› Author Affiliations
Further Information

Publication History

Received: 05 April 1989

Accepted after revision 13 July 1989

Publication Date:
30 June 2018 (online)

Summary

The amino terminal fragment (ATF) of urokinase-type plasminogen activator (uPA) is a degradation product comprising the entire growth factor-like and kringle domains. It has been previously shown that ATF is able to bind to the u-PA receptor through the growth factor-like domain and that the anti u-PA monoclonal antibody 5B4 (Mab 5B4) binds to ATF preventing u-PA receptor binding. To localize more precisely the epitope recognized by Mab 5B4, ATF was subfragmented by controlled enzymatic proteolysis with V8 protease.

Three subfragments of 4,000 Mr (F-4k), 11,000 Mr (F-llk) and 12,0 Mr (F-12k) were purified from the reaction mixture and characterized. SDS-PAGE under reducing and non-reducing conditions, N-terminal aminoacid sequence analysis and C-terminal aminoacid analysis of each fragment indicate that F-4k and F-llk correspond to intact growth factor-like domain and kringle domain (residues 4-43 and 44-135 respectively) while F-12k corresponds to the kringle. domain cleaved in the first loop at the glu52-gly53 bond.

By Western blot and competitive binding experiments we show that Mab 5B4 recognizes an epitope located on the kringle domain of u-PA and that the binding is strongly reduced when the kringle contains an additional cleavage in its first loop.

Since the receptor binding site of u-PA has been previously shown to be located on the growth factor-like domain, Mab 5B4 inhibits the binding of uPA to its cellular receptor likely by steric hindrance.

Besides the proven utility in epitope localization of anti u-PA monoclonal antibodies, these u-PA fragments may represent powerful tools for studies of structure-function relationship of u-PA.

 
  • References

  • 1 Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-265
  • 2 Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high molecular weight form of urokinase from urine. Arch Biochem Biophys 1983; 220: 31-38
  • 3 Stump DC, Thienpont M, Collen D. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. J Biol Chem 1986; 261: 1267-1273
  • 4 Corti A, Nolli ML, Soffientini A, Cassani G. Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from A431 cells. Thromb Haemostas 1986; 56: 219-224
  • 5 Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
  • 6 Nielsen LS, Hansen JG, Skriver I, Wilson EL, Kaltoff K, Zeuthen J, Dano K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982; 21: 6410-6415
  • 7 Kohno T, Hopper P, Lillquist JS, Suddith RL, Greenlee R, Moir DT. Kidney plasminogen activator: a precursor form of human urokinase with high fibrin affinity. Biotechnology 1984; 2: 628-634
  • 8 Eaton DL, Scott RW, Baker JB. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease-nexin. J Biol Chem 1984; 259: 6241-6247
  • 9 Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of single-chain prourokinase induces conformational changes which follow activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377-12381
  • 10 Stump DC, Lijnen HR, Collen D. Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. J Biol Chem. 1986; 261: 1274-1278
  • 11 Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F. The human urokinase plasminogen activator gene and its promoter. Nucl Acid Res 1985; 13: 2759-2771
  • 12 Tripputi P, Blasi F, Verde P, Cannizzaro LA, Emanuel BS, Croce CM. Human urokinase gene is located on the long arm of chromosome 10. Proc Natl Acad Sci USA 1985; 82: 4448-4452
  • 13 Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 1985; 41: 657-663
  • 14 Blasi F, Riccio A, Sebastio G. Human plasminogen activators. Gene and protein structure. In: Human genes and diseases. Blasi F. (ed). John Wiley; New York: 1986. pp 377-414
  • 15 Strassburger W, Wollmen A, Pitts JE, Glover ID, Tickle IJ, Blundell TL, Steffens GJ, Guenzler WA, Otting F, Flohe L. Adaptation of plasminogen activator sequences to known protease structures. FEBS Lett 1983; 157: 219-223
  • 16 Guenzler WA, Steffens GJ, Otting F, Kim SM, Frankus E, Flohe L. The primary structure of high molecular mass urokinase from human urine. The complete aminoacid sequence of the A chain. Hoppe-Seyler's Z Physiol Chem 1982; 363: 1155-1165
  • 17 Appella E, Weber IT, Blasi F. Structure and function of epidermal growth factor-like regions in proteins. FEBS Lett 1988; 231: 1-4
  • 18 Patthy L, Trexler M, Vali Z, Banyai L, Varadi A. Kringles: modules specialized for protein binding. Homology of the gelatin-binding region of fibronectin with the kringle structure of proteases. FEBS Lett 1984; 171: 131-136
  • 19 Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr55,0 form of the human plasminogen activator urokinase. J Cell Biol 1985; 100: 86-92
  • 20 Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939-4943
  • 21 Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing V, Cassani G, Appella E, Blasi F. Autocrine saturation of prourokinase receptors on human A431 cells. Cell 1986; 45: 675-684
  • 22 Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 1986; 261: 15819-15822
  • 23 Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F. The receptor binding sequence of urokinase. J Biol Chem 1987; 262: 4437-4440
  • 24 Nolli ML, Corti A, Soffientini A, Cassani G. A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator. Thromb Haemostas 1986; 56: 214-218
  • 25 Corti A, Nolli ML, Cassani G. Differential detection of single-chain and two-chain urokinase-type plasminogen activator by a new immuno-adsorbent amidolytic assay (I A A). Thromb Haemostas 1986; 56: 407-410
  • 26 Jones BN. Aminoacid analysis by o-phthaldialdehyde precolumn derivatization and reverse-phase HPLC. In: Methods of Protein Microcharacterization. Shively JE. (ed). Humana Press; Clifton, New Jersey: 1986. pp 121-151